Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.

Bauer, Karin; Berger, Daniela; Zielinski, Christoph C; Valent, Peter; Grunt, Thomas W

Bauer, Karin; Berger, Daniela; Zielinski, Christoph C; Valent, Peter; Grunt, Thomas W.

Afiliación

Bauer K; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Berger D; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Zielinski CC; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Valent P; Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Grunt TW; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Oncotarget ; 9(41): 26491-26506, 2018 May 29.

Article en En | MEDLINE | ID: mdl-29899872

Palabras clave

BRD4 degrader; JQ1; dBET1; drug combination; ponatinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Austria

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google